Thyroid Eye Disease
Recorded On: 12/18/2019
Commercial Support: Horizon
Thyroid Eye Disease (TED) is a serious, progressive autoimmune disease with a limited window for pharmacologic treatment, during the active disease. During this window, the disease may respond to pharmacologic intervention. With the potential of new infusion delivered treatment options on the horizon, it will be incumbent upon nurses and other healthcare providers to understand the disease state, as well as the treatment modalities. INS is of the belief that this need is best met and served through the development and delivery of nursing education programs.
At the conclusion of this webinar, learners will have an increased understanding of thyroid eye disease and the treatment options available for patients with this condition.
Terry J. Smith, M.D.
Frederick G.L. Huetwell Professor Ophthalmology and Visual Sciences
Dr. Terry J. Smith, MD, is an internationally known experimental and clinical endocrinologist. He has studied Graves’ disease, its ocular manifestations, and related autoimmune diseases for over 35 years. He and his colleagues have mapped the mechanisms involved in tissue changes occurring in thyroid-associated ophthalmopathy (TAO), a disfiguring and potentially blinding disease for which no FDA approved medications are currently available.
Contact Hours: This session has been approved for 1 contact hour
Expiration date for receipt of contact hours: December 18, 2022